An evidence based review of Dupilumab in the treatment of moderate to severe asthma

•Dupilumab can reduce the risk of severe asthma exacerbations.•FEV1 values were improved with dupilumab treated groups when compared to placebo-treated groups.•Safety outcomes of dupilumab and placebo treated groups were compared and showed greater prevalence of injection site reaction in dupulimab treated group.•Future studies need to be focused on the concerns like the use of dupilumab in vulnerable population, evaluation of long term use and comparison of efficacy with other biologics which may facilitate wider acceptance globally.